Skip to content

Saturday, October 24, 2026

Top Stories Global Economy Markets Topics & Series Contributors Opinion

All desks ⌄

Economy & Finance

Economy Investing Central Banks Digital Currency Fintech Research & Analysis Technicals

Power & Business

Politics Business Law Insights & Views Governance Market Roundups

Science & Society

Technology Science Nature Health Life

In focus · trending topic

Zanidatamab

1 stories · following the connections

Oncologists review research displays at IFEMA MADRID during the ESMO Congress in Madrid, Spain. (AI-generated image / EconoTimes)

Zanidatamab Regimen Shows 39.8% Estimated Three-Year Survival

By Naomi CalderOct 24, 2026, 1:20 AM UTC

←1→Page 1 of 1

Connected markets

Follow the indicators behind the story.

Illustrative data · 06 Oct 2026, 08:00 UTC

Keep exploring

Business Revenue Federal Trade Commission LNG GTT Liquefied natural gas Verisk AccuLynx

Coverage

Global Economy Markets Technology Politics All news

Intelligence

Topics & Series Contributors Research

Company

About us Become a contributor Contact info@econotimes.com Editorial standards

© 2026 PUBLISH Holdings LLC.Privacy Terms of use Our standards

Home Markets Topics Search